Risk Assessment for Excipients for Enhanced Patient Safety - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Risk Assessment for Excipients for Enhanced Patient Safety
The author describes key considertions for a complete risk-assessment model and provides insight into a pending IPEC guideline in this area.


Pharmaceutical Technology
Volume 35, pp. s29-s33

Formulation challenges

The risk assessment for excipients associated with their use in drug-product formulation and use can only be adequately performed by the drug-product manufacturers. Generalizations around the route of administration, the function of the excipient in the formulation, and the characteristics of the type of API can be useful in identifying potentially high-risk excipients. However, many excipients can have multiple functions, in multiple formulations, and are used with different types of APIs. Just because an excipient manufacturer can point to a drug-product formulation where their excipient presents a lower risk does not mean the excipient will be of lower risk in other formulations.

It's crucial that the excipient manufacturer clearly communicate its expectations for the route of administration for the final drug product using its excipient to avoid additional risks. In most cases, excipient manufacturers do not have adequate experience and knowledge of the use and function of their excipients in all user formulation and drug-product manufacturing processes. Certain assumptions are necessary for the excipient manufacturer to design appropriate controls into their processes, but these assumptions should be transparent and clearly open for the user's evaluation.

Conclusion

Excipient makers and users should each use risk-management principles to prevent failures in the final drug product. Risk assessment will not identify the extent of GMP required for a particular excipient but will serve to strengthen the processes. The engineering design, process control, and GMPs form the prerequisite controls necessary to reduce the infinite possibility for failures to a smaller and more manageable number from whence risk assessment can serve to focus our attention toward the few opportunities for failure in the absence of heightened control. Well-functioning GMPs have layers of checks and balances built into the procedures and processes to ensure that a single lapse at one point will likely not result in failure or necessitate a withdrawal of product.

Overall, risk assessment provides a tool to evaluate the status quo and find the opportunities to make the good better. Risk assessment brings an obligation for action to protect the patient because once a significant risk is identified, it cannot be ignored.

Regulatory bodies and excipient users may benefit from focusing their limited resources on higher-risk excipients as determined from a risk assessment based on available information. Assigning a higher risk to an excipient that in reality has a lower risk when sourced from a specific manufacturing facility due to advanced engineering and the unique processes utilized carries little consequence to the patient or drug manufacturer.

The opposite result of designating an excipient a lower risk when in actuality significant risk exists due to the particulars of its manufacturing process or facility introduces potential to harm the patient and drug maker. In the interest of patient safety, excipient risk characterizations must come from a proper and complete risk assessment, including consideration of the specific manufacturing locations and supply chains.

Pending IPEC guideline. IPEC–Americas is developing a guideline for excipient risk management in conjunction with the global IPEC Federation. This guide will explore risk management from both the makers' and users' perspective. The guide will outline the process, structure, and documentation necessary to demonstrate the effective application of risk management principles. The current ANSI NSF 363 stand-alone excipient GMP draft standard, and EXCIPACT ISO 9001 Annex Certification Standard for Excipient GMP, require documented risk assessments at several points to justify the application of certain GMP controls (3, 4). These standards are scheduled to become publically available in 2011 and the IPEC Excipient Risk Management guideline will be a helpful reference for companies seeking GMP certification to either of these proposed standards.

Acknowledgments

W. Busch, DowWolff Cellulosics; L. Calhoun, King Pharmaceutical/Pfizer; G. Collins Jr., RT Vanderbilt; D. Fillar, Perrigo; F. Flynn, RT Vanderbilt; J. Garofalo, Avantor Performance Materials; R. Green, CP Kelco; S. Hernadez, Ashland Aqualon; L, Herzog, Asahi Kasei; D. Klug, sanofi-aventis; F. Murphy, Dow Chemical; B. McCarter, EMD Chemicals; P. Merrell, Jost Chemical; L. Milano, Genentech; RC Moreton, FinnBrit Consulting; C. Perini, ISP; D. Schoneker, Colorcon; I. Silverstien, IBS Consulting in Quality; R. Sulouff III, Ashland Aqualon; A. Van Meter, Dow Chemical; P. Zawislak, Ashland Aqualon.

W. Dale Carter is chair of the International Pharmaceutical Excipients Council of the Americas (IPEC–Americas) and director of global quality-silica with Huber Engineered Materials in Atlanta, GA, tel. 678.247.2735.

References

1. ICH, Q9 Quality Risk Management (Geneva, November 2005).

2. J. Orloff, Pharm. Technol. 35 (2) 38–40 (2011).

3. ANSI NSF 363 (September 2009).

4. EXCIPACT ISO 9001 (in development). EXCIPACT is a consortium of industry bodies including IPEC-Americas, IPEC–Europe, PQG, EFCG, and FECC.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here